Cargando…

Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia

Idiopathic hyperammonemia is a serious condition that can arise after induction of chemotherapy and is characterized by plasma ammonia levels greater than two times the normal upper limit but within the context of normal liver function. While this dangerous complication usually appears several weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayed, Mohamed, Patel, Nimesh, Al Turk, Yahia, Bradley, Patrick B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723723/
https://www.ncbi.nlm.nih.gov/pubmed/35003956
http://dx.doi.org/10.7759/cureus.20108
_version_ 1784625779420692480
author Fayed, Mohamed
Patel, Nimesh
Al Turk, Yahia
Bradley, Patrick B
author_facet Fayed, Mohamed
Patel, Nimesh
Al Turk, Yahia
Bradley, Patrick B
author_sort Fayed, Mohamed
collection PubMed
description Idiopathic hyperammonemia is a serious condition that can arise after induction of chemotherapy and is characterized by plasma ammonia levels greater than two times the normal upper limit but within the context of normal liver function. While this dangerous complication usually appears several weeks after the start of chemotherapy, we report a fatal case of idiopathic hyperammonemia that was detected only nine days after induction chemotherapy in a 22-year-old man with no liver pathology or other risks for hyperammonemia. The patient’s initial emergent presentation was altered mental status. Laboratory workup showed acute monoblastic leukemia and radiological investigation showed cerebral hemorrhagic foci secondary to leukostasis. He received leukoreduction apheresis and he was started on induction chemotherapy with daunorubicin and cytarabine. On the ninth day of induction chemotherapy, it was noted that he developed worsening neurological findings. Investigations showed significant elevation in ammonia level and associated cerebral edema. Although hyperammonemia was mitigated, the patient’s cerebral status worsened and he died 15 days after initial presentation. This case shows that critical hyperammonemia can occur quickly after chemotherapy induction and that strategies for preventing a rise in plasma ammonia are necessary.
format Online
Article
Text
id pubmed-8723723
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-87237232022-01-06 Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia Fayed, Mohamed Patel, Nimesh Al Turk, Yahia Bradley, Patrick B Cureus Oncology Idiopathic hyperammonemia is a serious condition that can arise after induction of chemotherapy and is characterized by plasma ammonia levels greater than two times the normal upper limit but within the context of normal liver function. While this dangerous complication usually appears several weeks after the start of chemotherapy, we report a fatal case of idiopathic hyperammonemia that was detected only nine days after induction chemotherapy in a 22-year-old man with no liver pathology or other risks for hyperammonemia. The patient’s initial emergent presentation was altered mental status. Laboratory workup showed acute monoblastic leukemia and radiological investigation showed cerebral hemorrhagic foci secondary to leukostasis. He received leukoreduction apheresis and he was started on induction chemotherapy with daunorubicin and cytarabine. On the ninth day of induction chemotherapy, it was noted that he developed worsening neurological findings. Investigations showed significant elevation in ammonia level and associated cerebral edema. Although hyperammonemia was mitigated, the patient’s cerebral status worsened and he died 15 days after initial presentation. This case shows that critical hyperammonemia can occur quickly after chemotherapy induction and that strategies for preventing a rise in plasma ammonia are necessary. Cureus 2021-12-02 /pmc/articles/PMC8723723/ /pubmed/35003956 http://dx.doi.org/10.7759/cureus.20108 Text en Copyright © 2021, Fayed et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Fayed, Mohamed
Patel, Nimesh
Al Turk, Yahia
Bradley, Patrick B
Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title_full Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title_fullStr Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title_full_unstemmed Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title_short Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia
title_sort unexplained fatal hyperammonemia in a patient with new diagnosis of acute monoblastic leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723723/
https://www.ncbi.nlm.nih.gov/pubmed/35003956
http://dx.doi.org/10.7759/cureus.20108
work_keys_str_mv AT fayedmohamed unexplainedfatalhyperammonemiainapatientwithnewdiagnosisofacutemonoblasticleukemia
AT patelnimesh unexplainedfatalhyperammonemiainapatientwithnewdiagnosisofacutemonoblasticleukemia
AT alturkyahia unexplainedfatalhyperammonemiainapatientwithnewdiagnosisofacutemonoblasticleukemia
AT bradleypatrickb unexplainedfatalhyperammonemiainapatientwithnewdiagnosisofacutemonoblasticleukemia